Skip to content
Screener

Theravance Biopharma TBPH Business Segments — Transaction Related Expenses Acquiree

Similar metrics at other companies

Vertex, Inc. logo
VERXSingle Reportable — Transaction Costs
-$5.98M-125%
Payoneer Global Inc. logo
PAYOSingle Reportable — Transaction Costs
$37.68M-7.1%
Claritev Corporation logo
CTEVReportable Segment — Transaction-related expenses
$0
Edgewise Therapeutics, Inc. logo
EWTXSingle Reportable — Other Labor Related Expenses
$14.73M+38.6%
Rigel Pharmaceuticals logo
RIGLSingle reportable segment — Commercial related expenses
$7.04M+31.9%
Rigel Pharmaceuticals logo
RIGLSingle reportable segment — Employee related expenses
$21M+7.5%

Other financials

Income statement

See full
Revenue$20.7M-20.9%
Operating income-$8.3M-204%
Net income-$5.9M-111%
EPS (diluted)-$0.11-110%

Balance sheet

See full
Cash & equivalents$219.8M-22.0%
Total debt$38.6M-17.0%
Total equity$289.7M+28.8%
Total assets$469.8M+10.3%

Cash flow

See full
Operating cash flow$73.3M+70.3%
CapEx$8.0K-95.8%
Free cash flow$59.6M+5,560%

Valuation

See full
Market cap$877.45M+53.9%
Enterprise value$696.26M+108%
P/E16.3×-27.4×
P/S8.4×+1.0×

Profitability

See full
Gross margin60.8%
Operating margin-4%-1.9pp
Net margin51.6%+34.7pp
FCF margin221.9%+206pp

Returns & leverage

See full
Return on equity20.9%+14.7pp
Debt / equity0.1×-0.1×
Current ratio13.5×+6.8×

Where this comes from

Reported directly by Theravance Biopharma in its filing.

Tagged under the XBRL concept tbph:TransactionRelatedExpensesAcquiree.

The source filing: Theravance Biopharma’s 10-Q, filed August 11, 2026.

Filed
Aug 11, 2026, 8:00 AM EDT
Fiscal quarter
Q2 FY2026
Calendar quarter
Q2 2026
Accession
0001104659-26-093773
Line itemThree Months Ended June 30, 2026Three Months Ended June 30, 2025Six Months Ended June 30, 2026Six Months Ended June 30, 2025
Research and development (1)4,71210,49010,54121,942
Selling, general and administrative (1)14,17618,43031,89636,800
Restructuring expenses (1) (2)4,0317,664
Transaction-related expenses6,0896,089
Total expenses29,00828,92056,19058,742
Loss from operations(8,277)(2,725)(17,760)(17,159)
Net gain on realized contingent milestone and royalty assets75,13775,137
Interest expense (non-cash)(663)(1,306)

Item 1. Financial Statements (unaudited)

FAQ

What is Theravance Biopharma's business segments — transaction related expenses acquiree?
Theravance Biopharma (TBPH) reported business segments — transaction related expenses acquiree of $6.09M in Q2 2026.
What does business segments — transaction related expenses acquiree mean?
This metric tracks the non-recurring costs and professional fees incurred by the company specifically related to the acquisition of another entity or business unit. These expenses typically include legal, advisory, and integration costs associated with inorganic growth strategies. Analyzing these costs allows investors to evaluate the financial impact of M&A activity on the company's operational profitability.

Ask your AI about Theravance Biopharma's business segments — transaction related expenses acquiree.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude